We have located links that may give you full text access.
JOURNAL ARTICLE
REVIEW
Molecular "Sameness" Is the Key Guiding Principle for Extrapolation to Multiple Indications.
Much has been made of biosimilars as a new regulatory concept, yet it is clear that misunderstandings are widespread, including the scientific justification for use in all indications of the reference product or "extrapolation." However, as this article shows, biosimilarity and extrapolation are not new concepts and most patients being treated with a branded biologic have already received a similar version of the original reference biologic based on changes in the manufacturing process.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app